Are endometrial mesenchymal stem cells a better efficacious and safer blood-compatible MSC source?

Global Market Insights estimates the mesenchymal stem cells (MSCs) market size to grow from USD 3 billion in 2022 to USD 10.3 billion by 2032 due to the rising prevalence of chronic diseases. As of 2023, more than 1500 MSCs-based clinical trials have been registered in ClinicalTrials.gov. Almost half of the application is delivered intravascularly. This project looks to 1) characterise the haemocompatibility profile of endometrial-derived MSC and 2) determine if they are compatible with human whole blood for intravascular mode of administration. This project utilises cell culture and in-vitro disease models of infection and inflammation (key culprits to most diseases) and assesses whether endometrial MSCs are safe to treat diseases through intravascular mode. Techniques: Stem cell isolation, sterile cell culture, flow cytometry, Western Blotting, RT-PCR, quantitative and qualitative measurement of clotting elasticity.